Biosimilar drugs can reduce costs but still face challenges in the US

Biologics used to treat patients can be incredibly expensive, so there was significant hope that biosimilar drugs—which are highly similar to an existing biologic drug on the market—could serve as a less-costly substitute. However, new research from the University of Minnesota and Mayo Clinic finds that while physicians are indeed willing to prescribe these drugs, the cost savings are minor and there remains a number of regulatory barriers to their use.